Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of inhaled PC945 in adult cystic fibrosis patients with persistent pulmonary Aspergillus fumigatus infection
2018-000243-87Phase 2Terminated
- Sponsor
- Pulmocide
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of opelconazole in pulmonary aspergillosis and cystic fibrosis (CF), sponsored by Pulmocide. Primary endpoints: Safety and tolerability, Pharmacokinetics of PC945 and 1 more. Started Aug 2018; status: terminated.
02
Drugs
opelconazole
03
Conditions
pulmonary aspergillosiscystic fibrosis (CF)
Beyond the preview
Go deeper on 2018-000243-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000243-87.